Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancer-Reference-Cited by-同舟云学术

Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancer

Published:2023-11-02 Issue:1 Volume:38 Page:
ISSN:1475-6366
Container-title:Journal of Enzyme Inhibition and Medicinal Chemistry
language:en
Short-container-title:Journal of Enzyme Inhibition and Medicinal Chemistry

Author:

Sharma Sachin¹,Chandra Kavya²,Naik Aliva³,Sharma Anamika³,Sharma Ram¹,Thakur Amandeep¹,Grewal Ajmer Singh⁴,Dhingra Ashwani K.⁴,Banerjee Arnab²,Liou Jing Ping¹⁵,Guru Santosh Kumar³,Nepali Kunal¹⁵

Affiliation:

1. School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan

2. Department of Biological Sciences, BITS Pilani KK Birla Goa campus, Goa, India

3. Department of Biological Sciences, National Institute of Pharmaceutical Education and Research, Hyderabad, India

4. Guru Gobind Singh College of Pharmacy, Yamuna Nagar, India

5. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan

Funder

Ministry of Science and Technology, Taiwan

National Science and Technology Council

SERB

DBT, GOI

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14756366.2023.2276665

Reference70 articles.

1. Evolution of uncontrolled proliferation and the angiogenic switch in cancer

2. Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost

3. Environmental causes of cancer: endocrine disruptors as carcinogens

4. The Causes of Cancer: Quantitative Estimates of Avoidable Risks of Cancer in the United States Today

5. What Causes Cancer?

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ACOT7 positively regulated by CREB1 promotes the progression of cutaneous melanoma;Acta Histochemica;2024-10

2. European Journal of Medicinal Chemistry Rationally Designed Febuxostat-Based Hydroxamic Acid and its pH-Responsive Nanoformulation Elicits Anti-Tumor Activity;European Journal of Medicinal Chemistry;2024-09

3. Dual-target inhibitors of colchicine binding site for cancer treatment;European Journal of Medicinal Chemistry;2024-08

4. Leveraging a rationally designed veliparib-based anilide eliciting anti-leukemic effects for the design of pH-responsive polymer nanoformulation;European Journal of Medicinal Chemistry;2024-07